Moderna shares plunge as leaked cancer vaccine data disappoints

In the latest trial, which enrolled more than 1100 patients, the mRNA vaccine was given to patients at high risk for recurrence after their melanoma was surgically removed. They…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.afr.com)